Encephalitis Clinical Trials

Find Encephalitis Clinical Trials Near You

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Age 18-80 years;

• meeting clinical criteria for possible AE with identified antibodies;

• newly diagnosed with symptoms \<6 months;

• no second-line immunosuppressive treatment;

• high or mixed TSPO binding affinity phenotype.

Locations
Other Locations
France
University Hospital
RECRUITING
Toulouse
Contact Information
Primary
Marie Rafiq, MD
rafiq.m@chu-toulouse.fr
+33 561779491
Time Frame
Start Date: 2026-03-31
Estimated Completion Date: 2028-01
Participants
Target number of participants: 40
Treatments
Experimental: patients with Autoimmune encephalitis
patients with Autoimmune encephalitis
Experimental: control
control
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Toulouse

This content was sourced from clinicaltrials.gov